Ivabradine Versus Digitalis Glycosides in Heart Failure With Reduced Ejection Fraction: A Comparative Appraisal of Two Additional Medical Therapies

Abstract Purpose Resting heart rate predicts outcome in heart failure (HF) with reduced ejection fraction (HFrEF), but lowering it benefits only hemodynamically stable patients. This narrative review compares ivabradine and the digitalis glycosides, the only additional medical therapies in the 2026 ESC guidelines that slow the heart rate, as add-ons to foundational medical therapy (FMT). Methods We searched PubMed and the Cochrane Library through August 2026 and current guidelines, giving greatest weight to large randomized trials and contemporary meta-analyses. Results Ivabradine reduced cardiovascular death or heart-failure hospitalization (HR 0.82, 95% CI 0.75–0.90) without a mortality benefit; it is restricted to sinus rhythm with LVEF ≤ 35% and heart rate ≥ 70 bpm (Class IIa B1). The digitalis glycosides act in any rhythm, with LVEF ≤ 40% (Class IIa B1), and reduce worsening-heart-failure events (pooled HR 0.75, n = 9,013) without affecting mortality, within narrow, agent-specific therapeutic windows (digoxin 0.5–0.9 ng/mL; digitoxin 8–18 ng/mL). DIGIT-HF (digitoxin) was positive and DECISION (digoxin) neutral; their estimates are similar in direction and magnitude, but differences in drug, population and endpoint preclude calling them concordant. Digoxin withdrawal is associated with deterioration, although contemporary data rest on few events. Conclusion Ivabradine and the digitalis glycosides are not symmetric alternatives. Ivabradine is a narrow add-on for sinus-rhythm patients who remain tachycardic despite beta-blockade; the glycosides serve both ventricular rate control in atrial fibrillation and prevention of worsening HF irrespective of rhythm. Both reduce morbidity rather than mortality and belong only after FMT is optimized. No randomized trial has compared them directly.

Authors

Institutions

Publication Details

Journal
Cardiovascular Drugs and Therapy
Published
2026-11-17
DOI
https://doi.org/10.1007/s10557-026-07989-x
Primary Topic
Heart rate and cardiovascular health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ivabradine Versus Digitalis Glycosides in Heart Failure With Reduced Ejection Fraction: A Comparative Appraisal of Two Additional Medical Therapies

Luca Fazzini, Gregorio Tersalvi, Mattia Arrigo, Marco Bergonti et al.
Cardiovascular Drugs and Therapy
Heart rate and cardiovascular health
article

Ivabradine Versus Digitalis Glycosides in Heart Failure With Reduced Ejection Fraction: A Comparative Appraisal of Two Additional Medical Therapies

Luca Fazzini, Gregorio Tersalvi, Mattia Arrigo, Marco Bergonti, Vittorio Beltrani, Giordano Maria Pugliesi, Martin R. Gruebler
article en

Abstract

Abstract Purpose Resting heart rate predicts outcome in heart failure (HF) with reduced ejection fraction (HFrEF), but lowering it benefits only hemodynamically stable patients. This narrative review compares ivabradine and the digitalis glycosides, the only additional medical therapies in the 2026 ESC guidelines that slow the heart rate, as add-ons to foundational medical therapy (FMT). Methods We searched PubMed and the Cochrane Library through August 2026 and current guidelines, giving greatest weight to large randomized trials and contemporary meta-analyses. Results Ivabradine reduced cardiovascular death or heart-failure hospitalization (HR 0.82, 95% CI 0.75–0.90) without a mortality benefit; it is restricted to sinus rhythm with LVEF ≤ 35% and heart rate ≥ 70 bpm (Class IIa B1). The digitalis glycosides act in any rhythm, with LVEF ≤ 40% (Class IIa B1), and reduce worsening-heart-failure events (pooled HR 0.75, n = 9,013) without affecting mortality, within narrow, agent-specific therapeutic windows (digoxin 0.5–0.9 ng/mL; digitoxin 8–18 ng/mL). DIGIT-HF (digitoxin) was positive and DECISION (digoxin) neutral; their estimates are similar in direction and magnitude, but differences in drug, population and endpoint preclude calling them concordant. Digoxin withdrawal is associated with deterioration, although contemporary data rest on few events. Conclusion Ivabradine and the digitalis glycosides are not symmetric alternatives. Ivabradine is a narrow add-on for sinus-rhythm patients who remain tachycardic despite beta-blockade; the glycosides serve both ventricular rate control in atrial fibrillation and prevention of worsening HF irrespective of rhythm. Both reduce morbidity rather than mortality and belong only after FMT is optimized. No randomized trial has compared them directly.

Cardiovascular Drugs and Therapy
Sigmund Freud Privatuniversität Wien (AT), Danube Private University (AT), Mayo Clinic (US), Medical University of Graz (AT), Ente Ospedaliero Cantonale (CH), Ospedale Papa Giovanni XXIII (IT), Ospedale Regionale di Mendrisio (CH), Azienda Ospedaliera San Gerardo (IT), Universitätsklinikum Wiener Neustadt (AT), Istituto Cardiocentro Ticino (CH), Università della Svizzera italiana (CH)
Heart rate and cardiovascular health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon